Citadel Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-18,745
| Closed | -$43.5K | – | 15528 |
|
|
2024
Q2 | $43.5K | Buy |
18,745
+5,459
| +41% | +$14.1K | ﹤0.01% | 11919 |
|
|
2024
Q1 | $37.5K | Buy |
+13,286
| New | +$39.4K | ﹤0.01% | 12466 |
|
|
2023
Q2 | – | Sell |
-15,548
| Closed | -$52.7K | – | 15421 |
|
|
2023
Q1 | $52.7K | Sell |
15,548
-2,343
| -13% | -$8.2K | ﹤0.01% | 12086 |
|
|
2022
Q4 | $64.6K | Buy |
+17,891
| New | +$117K | ﹤0.01% | 11812 |
|
|
2022
Q2 | – | Sell |
-11,339
| Closed | -$107K | – | 14361 |
|
|
2022
Q1 | $107K | Buy |
+11,339
| New | +$101K | ﹤0.01% | 12229 |
|
|
2021
Q4 | – | Sell |
-11,869
| Closed | -$113K | – | 14976 |
|
|
2021
Q3 | $113K | Buy |
+11,869
| New | +$111K | ﹤0.01% | 12719 |
|
|
2020
Q1 | – | Sell |
-3,366
| Closed | -$77K | – | 10328 |
|
|
2019
Q4 | $77K | Sell |
3,366
-140
| -4% | -$2K | ﹤0.01% | 8649 |
|
|
2019
Q3 | $50K | Sell |
3,506
-1,630
| -32% | -$23.9K | ﹤0.01% | 8705 |
|
|
2019
Q2 | $68K | Buy |
5,136
+1,810
| +54% | +$27.3K | ﹤0.01% | 8648 |
|
|
2019
Q1 | $58K | Buy |
3,326
+1,751
| +111% | +$26.1K | ﹤0.01% | 8767 |
|
|
2018
Q4 | $22K | Sell |
1,575
-3,447
| -69% | -$60.7K | ﹤0.01% | 8715 |
|
|
2018
Q3 | $108K | Sell |
5,022
-3,241
| -39% | -$98.6K | ﹤0.01% | 8542 |
|
|
2018
Q2 | $354K | Sell |
8,263
-943
| -10% | -$43.2K | ﹤0.01% | 6939 |
|
|
2018
Q1 | $601K | Buy |
9,206
+219
| +2% | +$15.5K | ﹤0.01% | 5588 |
|
|
2017
Q4 | $656K | Buy |
8,987
+6,589
| +275% | +$545K | ﹤0.01% | 5270 |
|
|
2017
Q3 | $220K | Sell |
2,398
-18,756
| -89% | -$1.44M | ﹤0.01% | 6554 |
|
|
2017
Q2 | $1.4M | Buy |
21,154
+15,361
| +265% | +$1.9M | ﹤0.01% | 3624 |
|
|
2017
Q1 | $1.26M | Buy |
+5,793
| New | +$828K | ﹤0.01% | 3663 |
|
|
2016
Q1 | – | Sell |
-221
| Closed | -$44.8K | – | 8186 |
|
|
2015
Q4 | $72K | Sell |
221
-5,864
| -96% | -$1.91M | ﹤0.01% | 7003 |
|
|
2015
Q3 | $1.96M | Buy |
6,085
+5,844
| +2,425% | +$2.57M | ﹤0.01% | 2968 |
|
|
2015
Q2 | $96K | Sell |
241
-10,445
| -98% | -$4.44M | ﹤0.01% | 7116 |
|
|
2015
Q1 | $5.26M | Buy |
10,686
+8,105
| +314% | +$3.14M | 0.01% | 1991 |
|
|
2014
Q4 | $923K | Buy |
2,581
+2,063
| +398% | +$614K | ﹤0.01% | 3868 |
|
|
2014
Q3 | $100K | Buy |
+518
| New | +$114K | ﹤0.01% | 6415 |
|
|
2014
Q2 | – | Sell |
-1,061
| Closed | -$216K | – | 8373 |
|
|
2014
Q1 | $271K | Buy |
1,061
+19
| +2% | +$5.81K | ﹤0.01% | 5135 |
|
|
2013
Q4 | $206K | Buy |
+1,042
| New | +$185K | ﹤0.01% | 4993 |
|
Other funds holding LUMO
PAG
JFG
GWM
LPC
Citadel Advisors's LUMO Position: Q3 2024 in Review
Citadel Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2024, closing a stake of 18,745 shares — an estimated $43.5K sold.
Citadel Advisors first reported a position in LUMO in Q4 2013 and held it in 26 quarters. The position peaked at $5.26M in Q1 2015. 28 funds tracked by Wall St. Rank hold LUMO as of Q3 2024.
- Citadel Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Citadel Advisors sold 18,745 Lumos Pharma, Inc. Common Stock shares in Q3 2024, an estimated $43.5K.
- Citadel Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2013 and held it in 26 quarters.
- Citadel Advisors's Lumos Pharma, Inc. Common Stock position peaked at $5.26M in Q1 2015.
- 28 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2024.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.